United Therapeutics Corporation (UTHR)
UTHR Stock Price Chart
Explore United Therapeutics Corporation interactive price chart. Choose custom timeframes to analyze UTHR price movements and trends.
UTHR Company Profile
Discover essential business fundamentals and corporate details for United Therapeutics Corporation (UTHR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
17 Jun 1999
Employees
1.31K
Website
https://www.unither.comCEO
Martine A. Rothblatt
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
UTHR Financial Timeline
Browse a chronological timeline of United Therapeutics Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 28 Apr 2026
Upcoming earnings on 24 Feb 2026
Upcoming earnings on 29 Oct 2025
EPS estimate is $6.75.
Earnings released on 30 Jul 2025
EPS came in at $6.41 falling short of the estimated $6.80 by -5.74%, while revenue for the quarter reached $798.60M , missing expectations by -2.24%.
Earnings released on 30 Apr 2025
EPS came in at $6.63 surpassing the estimated $6.29 by +5.41%, while revenue for the quarter reached $794.40M , beating expectations by +2.02%.
Earnings released on 26 Feb 2025
EPS came in at $6.19 falling short of the estimated $6.40 by -3.28%, while revenue for the quarter reached $735.90M , beating expectations by +0.16%.
Earnings released on 30 Oct 2024
EPS came in at $6.39 falling short of the estimated $6.43 by -0.62%, while revenue for the quarter reached $748.90M , beating expectations by +3.64%.
Earnings released on 31 Jul 2024
EPS came in at $5.85 falling short of the estimated $6.40 by -8.59%, while revenue for the quarter reached $714.90M , beating expectations by +3.33%.
Earnings released on 1 May 2024
EPS came in at $6.17 surpassing the estimated $5.65 by +9.20%, while revenue for the quarter reached $677.70M , beating expectations by +8.61%.
Earnings released on 21 Feb 2024
EPS came in at $4.36 surpassing the estimated $4.19 by +4.06%, while revenue for the quarter reached $614.70M , beating expectations by +6.74%.
Earnings released on 1 Nov 2023
EPS came in at $5.38 surpassing the estimated $5.04 by +6.75%, while revenue for the quarter reached $609.40M , beating expectations by +3.66%.
Earnings released on 2 Aug 2023
EPS came in at $5.24 surpassing the estimated $4.51 by +16.19%, while revenue for the quarter reached $596.50M , beating expectations by +13.80%.
Earnings released on 3 May 2023
EPS came in at $4.86 surpassing the estimated $4.52 by +7.52%, while revenue for the quarter reached $506.90M , missing expectations by -1.45%.
Earnings released on 22 Feb 2023
EPS came in at $2.67 falling short of the estimated $4.51 by -40.80%, while revenue for the quarter reached $491.50M , missing expectations by -5.34%.
Earnings released on 2 Nov 2022
EPS came in at $4.91 surpassing the estimated $3.89 by +26.22%, while revenue for the quarter reached $516.00M , beating expectations by +4.62%.
Earnings released on 3 Aug 2022
EPS came in at $2.41 falling short of the estimated $4.13 by -41.65%, while revenue for the quarter reached $466.90M , beating expectations by +1.27%.
Earnings released on 4 May 2022
EPS came in at $5.03 surpassing the estimated $3.35 by +50.15%, while revenue for the quarter reached $461.90M , beating expectations by +9.96%.
Earnings released on 24 Feb 2022
EPS came in at $2.35 falling short of the estimated $3.72 by -36.83%, while revenue for the quarter reached $415.20M , missing expectations by -2.90%.
Earnings released on 3 Nov 2021
EPS came in at $3.42 falling short of the estimated $3.59 by -4.74%, while revenue for the quarter reached $444.70M , beating expectations by +1.51%.
Earnings released on 4 Aug 2021
EPS came in at $3.65 surpassing the estimated $3.02 by +20.86%, while revenue for the quarter reached $446.50M , meeting expectations.
Earnings released on 5 May 2021
EPS came in at $0.61 falling short of the estimated $2.94 by -79.25%, while revenue for the quarter reached $379.10M , beating expectations by +2.93%.
Earnings released on 24 Feb 2021
EPS came in at $2.19 falling short of the estimated $3.14 by -30.25%, while revenue for the quarter reached $384.90M , beating expectations by +7.72%.
Earnings released on 28 Oct 2020
EPS came in at $3.86 surpassing the estimated $2.83 by +36.40%, while revenue for the quarter reached $380.10M , beating expectations by +35.72%.
UTHR Stock Performance
Access detailed UTHR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.